Functional Fluidics biomarkers can objectively assess effects of red blood cell therapies in clinical trials.
Functional Fluidics biomarkers can determine the effects of your experimental therapy on red blood cell function and assess dose-dependent pharmacodynamic effects in the context of clinical trials by assessing blood samples from study subjects treated with your therapy.
Our goal is to support our partners in completing this phase to bring safe, life changing therapies to market.
Proprietary Lab Developed Tests
Whether your drug is in preclinical development or it already been approved by the FDA, healthcare providers will need well-validated biomarkers to objectively assess the impact on red blood cell health, and ultimately patient health. Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.
- Flow Adhesion:
Our Flow Adhesion Assays capture the adhesive properties of an individual’s blood cells during conditions that simulate physiologic blood flow.
- Mechanical Fragility (MF):
Our Membrane Fragility assay determines the stability of the intact RBC membrane, which indicates the health of the RBC and may predict RBC survival.
Functional Fluidics Assays
Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.
Publications & Abstracts
Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease
Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dosedependent manner
Impact of environment on Red Blood Cell ability to withstand mechanical stress
An approach to measuring RBC haemolysis and profiling RBC mechanical fragility
Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay
A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease